Analysis
Inoviq (IIQ.AX) has not reported a material financial impact from the U.S. tariffs introduced in April 2025, although the company identifies trade policy and customs duties as a persistent regulatory risk. The company's core operations are focused on the research and development of exosome-based diagnostics and therapeutics, which are primarily centered in Australia, with a 100% owned subsidiary (INOVIQ Inc.) and a distribution partner (Promega Corporation) managing U.S. activities.
The 10% baseline tariff on imports to the U.S. and the subsequent reciprocal tariffs announced on April 2, 2025, coincide with a period where Inoviq reported continued growth in its EXO-NET research tool revenue, which increased to $253,261 in FY2025 from $201,863 in FY2024. This growth suggests that the tariffs have not significantly hindered the demand or commercial roll-out of its research tools. Furthermore, initial U.S. trade policy in early 2025 provided temporary exemptions for pharmaceutical and certain medical supplies, a category that likely encompassed Inoviq's diagnostic adjuncts and research tools.
In its FY2025 Annual Report, released in August 2025, Inoviq maintained its standard risk disclosure regarding changes in government legislation and policy, specifically noting that changes in tariffs could affect future earnings and asset values. However, management has not highlighted any specific pricing adjustments, supply chain disruptions, or volume declines attributed to the April 2025 tariff actions. The company's primary value driver remains its clinical and preclinical pipeline, including the EXO-OC ovarian cancer screening test and CAR-exosome therapeutics, which are less sensitive to import duties than high-volume physical commodities.
Inoviq's strategic focus for FY2026 includes expanding its U.S. commercial footprint for the EXO-OC test as a Laboratory Developed Test (LDT). Because LDTs are typically performed within a single laboratory (often using local reagents or specialized kits), this model may provide some natural mitigation against broad import tariffs compared to a traditional distributed In Vitro Diagnostic (IVD) kit model. Additionally, the company's collaboration with the U.S.-based Promega Corporation allows it to leverage an established domestic distribution network, which may help absorb or navigate administrative overhead related to new trade barriers.
Sources
Changes in government legislation and policy in those jurisdictions in which INOVIQ operates or plans to operate, in particular changes in taxation, royalties, compliance with environmental regulations, export, workplace health and safety, chain of responsibility, intellectual property, customs, tariffs, franchising and competition laws, may affect the future earnings, asset values and the relative attractiveness of investing in INOVIQ.
EXO-NET revenue and customers grew across Europe, US and Asia via global partner Promega Corporation.